Document Detail

Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants.
MedLine Citation:
PMID:  23354809     Owner:  NLM     Status:  Publisher    
OBJECTIVES: To develop population pharmacokinetic (PK) models for piperacillin/tazobactam in neonates and infants of less than 2 months of age in order to determine the appropriate dosing regimen and provide a rational basis for the development of preliminary dosing guidelines suitable for this population. METHODS: A two-stage, open-label study was conducted in neonates and infants less than 2 months of age in the neonatal intensive care unit (NICU). A total of 207 piperacillin and 204 tazobactam concentration-time data sets from 71 patients were analyzed using a nonlinear mixed-effect modeling approach (NONMEM VII). PK models were developed for piperacillin and tazobactam. The final models were evaluated using both bootstrap and visual predictive checks. External model evaluations were made in 20 additional patients. RESULTS: For neonates and young infants less than 2 months of age, the median central clearance was 0.133 and 0.149 L/h/kg for piperacillin and tazobactam, respectively. Postmenstrual age (PMA) was identified as the most significant covariate on central clearance of piperacillin and tazobactam. However, the combination of current bodyweight (BW) and postnatal age proved to be superior to PMA alone. BW was the most important covariate for apparent central volume of distribution. Both internal and external evaluations supported the prediction of the final piperacillin and tazobactam PK models. The dosing strategy 44.44/5.56 mg/kg/dose piperacillin/tazobactam every 8 or 12 h evaluated in this study achieved the pharmacodynamic target (free piperacillin concentrations >4 mg/L for more than 50 % of the dosing interval) in about 67 % of infants. CONCLUSIONS: Population PK models accurately described the PK profiles of piperacillin/tazobactam in infants less than 2 months of age. The results indicated that higher doses or more frequent dosing regimens may be required for controlling infection in this population in NICU.
Zhiping Li; Yewei Chen; Qin Li; Di Cao; Wenjing Shi; Yun Cao; Dan Wu; Yiqing Zhu; Yi Wang; Chao Chen
Related Documents :
7408369 - Congenital asymmetrical crying facies.
9192419 - Congenital syphilis associated with hyperlipoproteinemia.
3379279 - Infarction of the upper limbs associated with oligohydramnios and intrauterine compress...
20956899 - Congenital muscular torticollis: experience of 14 cases.
25419969 - Sustained inflation at birth did not alter lung injury from mechanical ventilation in s...
9241479 - Congenital malaria: an african survey.
16024159 - Prognosis in cervical insufficiency at less than 32 weeks of gestation.
9920169 - Long-term storage at -80 degrees c of hematopoietic progenitor cells with 5-percent dim...
22070139 - Preterm birth seasonality in greece: an epidemiological study.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-26
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  -     ISSN:  1432-1041     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Pharmacy, Children's Hospital of Fudan University, Shanghai, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Patient perspectives on type 2 diabetes and medicine use during Ramadan among Pakistanis in Denmark.
Next Document:  Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients...